TYK2 Pseudokinase Ligands Stabilizing Auto-Inhibitory Conformation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and autoimmune diseases, particularly those mediated by the JAK-STAT pathway, lack effective inhibitors for TYK2, a key kinase involved in cytokine signaling, leading to insufficient control of conditions like rheumatoid arthritis, multiple sclerosis, and psoriasis.
Innovation Solution
Development of compounds of Formula (I), (II), (III), and (IV) that act as TYK2 pseudokinase ligands, specifically designed to modulate the activity of TYK2 by stabilizing its auto-inhibitory conformation, thereby inhibiting cytokine signaling and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory and autoimmune diseases are used, then existing therapeutic options are available, but effective inhibition of TYK2 is lacking leading to insufficient control of disease conditions
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure parameters of TYK2 inhibitors. The compounds feature specific structural parameters including a heteroaryl or cycloalkyl group (parameter 1), a linker L1 (parameter 2), and a terminal group with L2 (parameter 3), where each parameter can vary within defined ranges to optimize TYK2 inhibition while maintaining selectivity and pharmacological properties
Solution Approach 2:
The patent applies local quality by designing compounds with distinct functional regions that perform specific roles: the heteroaryl/cycloalkyl group (parameter 1) provides target binding affinity, the linker L1 (parameter 2) provides structural connectivity and flexibility, and the terminal group with L2 (parameter 3) provides additional binding interactions. This localized functional differentiation enables selective and effective TYK2 inhibition
2Reliability
If TYK2 activity is inhibited to treat inflammatory diseases, then therapeutic benefits are achieved, but potential off-target effects on other JAK family members may occur
Solution Approach 1:
The patent applies local quality by designing the compound structure with specific local features that match the TYK2 binding pocket geometry and chemical environment. The heteroaryl/cycloalkyl group (parameter 1) is positioned to interact with TYK2-specific residues, while the linker L1 (parameter 2) and terminal group with L2 (parameter 3) are configured to form local interactions that are selective for TYK2 over other JAK family members, thereby achieving targeted inhibition with reduced off-target effects
Data Source
AI summary
Described herein are TYK2 pseudokinase ligands and methods of utilizing TYK2 pseudokinase ligands in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.